Press releases – Oncopeptides

First patient dosed in the pivotal phase III study OCEAN with Ygalo® (melflufen)

June 14, 2017

Stockholm - June 14, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the first patient has been dosed in the pivotal phase III study OCEAN. The study is targeting Late-Stage Relapsed...

Bulletin from the Annual General Meeting in Oncopeptides AB (Publ)

May 18, 2017

Stockholm, Sweden – 18 May 2017 — Oncopeptides AB’s (ONCO) annual general meeting 2017 was held today, at IVA Conference center in Stockholm. At the meeting, the following principal resolutions were passe...

Oncopeptides AB Interim Report January – March 2017

May 18, 2017

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2017 report. ”Our IPO received strong interest both from Sweden and internationally, including several wel...

Change in number of shares and votes in Oncopeptides AB (publ)

April 28, 2017

During April, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 977 906 shares and votes due to the new issue of shares...

Annual General Meeting in Oncopeptides AB (publ)

April 18, 2017

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438 (“Oncopeptides” or the “Company”), are hereby given notice to attend the Annual General Meeting to be held in the Banquet room at IVA Con...

Oncopeptides AB issues 977,906 shares additionally in connection with offer to acquire shares and listing on Nasdaq Stockholm (the “Offering”)

March 27, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

ABG Sundal Collier AB exercises the over-allotment option regarding 977,906 shares in Oncopeptides AB (publ)

March 24, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected.

March 22, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Fourth member of Oncopeptides’ Nomination Committee appointed for the 2017 AGM

March 22, 2017

Stockholm - March 22, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the composition of the Nomination Committee has now been completed.

Additional patent protection for Ygalo granted in Europe until 2032

March 21, 2017

Stockholm - March 21, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the European Patent Office (EPO) recently issued a notice that they intend to grant an additional European patent...

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected.

March 13, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) (“Oncopeptides” or the ”Company”) that stabilisation measures regarding the Company’s shares have been effected.

March 2, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Change in number of shares and votes in Oncopeptides AB (publ)

February 28, 2017

During February, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 16,786,215 shares and votes due to the new issues of shares that were made in...

Company’s CEO Acquires Shares in Oncopeptides

February 24, 2017

Stockholm, Sweden - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the company's CEO, Jakob Lindberg acquired 45,000 shares in Oncopeptides for a value of SEK 1.9M in addition to the shares...

Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today

February 22, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm

February 8, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

First patients are now enrolled in HORIZON, Oncopeptides’ Phase II Clinical Trial in Late Stage Relapsed and Refractory Multiple Myeloma

January 19, 2017

Oncopeptides AB, a clinical stage pharmaceutical company, developing the peptidase potentiated therapy Ygalo (melflufen), announced that the clinical development program is continuing according to plan....

Notice to attend an extraordinary shareholders’ meeting in Oncopeptides AB (Publ)

January 4, 2017

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, are hereby given notice to attend an extraordinary shareholders’ meeting to be held at the company’s premises on Västra Trädgårdsgatan 15 in ...